PubMed’s first selective growth hormone secretagogue paper on ipamorelin, plus the FDA record
Here are the sources I link to, with a few words about what each one covers. The limits are useful too: a paper can answer its own question without answering every claim about the pair.
Studies of signals and exposure
CJC-1295 in people
Teichman and colleagues, 2006 studied CJC-1295 with DAC in healthy adults, measuring hormone levels and safety. Ionescu and Frohman, 2006 examined hormone pulses during sustained exposure. Neither study tested the fixed blend or established better sleep and recovery.
Ipamorelin on its own
Raun and colleagues, 1998 compared hormone responses in animals. Gobburu and colleagues, 1999 studied ipamorelin given into a vein in human volunteers. These answer different questions: selective hormone release in animals and what happens after a particular human exposure.
Related signals together
Bowers and colleagues, 1990 studied related hormone-releasing signals together in men. The combined hormone response was larger than simple addition. That helps explain the interest in pairing pathways, but the experiment didn’t use CJC-1295 and ipamorelin.
Class context and another GHRH-related substance
Sigalos and Pastuszak, 2018 reviewed growth hormone secretagogues—drugs that encourage hormone release—including blood-sugar concerns and limited long-term safety evidence. Wilton and colleagues, 1993 studied GHRH(1–29) by intravenous and nasal routes. Neither supplies a regimen for the pair.
Documents about the actual material and its status
Formulation and safety assessments
The FDA’s December 2024 CJC-1295 briefing explains the different forms and reviews human evidence and safety. The October 2024 ipamorelin briefing examines quality, clinical findings and safety gaps. These are assessments, rather than drug approvals or instructions for use.
The FDA’s published safety page
The FDA safety page lists CJC-1295 as nominated but withdrawn. Ipamorelin acetate appears in that table and remains in Category 2 under the 503B policy for outsourcing facilities. April 22, 2026 is the page’s content date, not a withdrawal date. Withdrawal doesn’t mean clearance.
Material identity
Gajda and colleagues, 2019 identified altered secretagogues in seized material. Their results concern the samples examined. They don’t survey every preparation or tell us whether a particular mixture is suitable for human use.
Sermorelin’s historical record
The FDA’s 2013 Geref determination says sermorelin acetate’s former approved product wasn’t taken off sale for safety or effectiveness reasons. That historical finding doesn’t approve current compounded preparations or establish a use for CJC-1295 Ipamorelin.
None of these sources is a controlled human trial of the fixed pair. If you follow a link to check a claim, keep the substance, people or animals, route and measured outcome in view. Those details explain both what a study adds and where its answer stops.
These papers give us useful separate findings. The combination still needs its own human evidence.